Pfizer commits to Canadian Paralympics

Pharmaceutical company renews with CPC until 2019.

13 June 2017 Sam Carp
SHARE THIS ARTICLE

The Canadian Paralympic Committee (CPC) has extended its long-term partnership with Pfizer Canada until 2019.

According to SportBusinessDaily, the two-year renewal is worth more than CAD$1 million (US$754,000), and will focus on the health benefits of inclusive sports opportunities for all Canadians.

Under the terms of the agreement, the pharmaceutical company will support the Canadian Paralympic team and provide funding for the next generation of athletes through the Paralympic Foundation of Canada. 

The deal between the two parties extends a partnership which was first launched in 1996.

“This is a milestone moment for Paralympic sport in Canada,” said Marc-André Fabien, president of the CPC. “Our partnership with Pfizer Canada has grown from early beginnings when they directly helped fund Team Canada to get to the Paralympic Games, to now a broader and more sophisticated investment in Paralympic sport over the years.

“Truly, the continuous investment from Pfizer Canada has underpinned the growth and advancement of the Paralympic movement in Canada, and for that we are thrilled and grateful.”

John Helou, president of Pfizer Canada, added: “Pfizer Canada takes great pride in the athletes' remarkable achievements, both at the Paralympic Games and at the game of life. Paralympic athletes are more than just elite competitors; they are superb role models as well.

“We are proud of our commitment as key supporters of the Canadian Paralympic team and we wish athletes and coaches the very best in their quest for the podium at upcoming Games.”

The announcement comes almost a year after the Canadian Paralympic team matched their best-ever medal total of 22 at the Rio 2016 Summer Paralympics.   

The Canadian Paralympic Committee (CPC) has extended its long-term partnership with Pfizer Canada until 2019.

According to SportBusinessDaily, the two-year renewal is worth more than CAD$1 million (US$754,000), and will focus on the health benefits of inclusive sports opportunities for all Canadians.

Under the terms of the agreement, the pharmaceutical company will support the Canadian Paralympic team and provide funding for the next generation of athletes through the Paralympic Foundation of Canada. 

The deal between the two parties extends a partnership which was first launched in 1996.

“This is a milestone moment for Paralympic sport in Canada,” said Marc-André Fabien, president of the CPC. “Our partnership with Pfizer Canada has grown from early beginnings when they directly helped fund Team Canada to get to the Paralympic Games, to now a broader and more sophisticated investment in Paralympic sport over the years.

“Truly, the continuous investment from Pfizer Canada has underpinned the growth and advancement of the Paralympic movement in Canada, and for that we are thrilled and grateful.”

John Helou, president of Pfizer Canada, added: “Pfizer Canada takes great pride in the athletes' remarkable achievements, both at the Paralympic Games and at the game of life. Paralympic athletes are more than just elite competitors; they are superb role models as well.

“We are proud of our commitment as key supporters of the Canadian Paralympic team and we wish athletes and coaches the very best in their quest for the podium at upcoming Games.”

The announcement comes almost a year after the Canadian Paralympic team matched their best-ever medal total of 22 at the Rio 2016 Summer Paralympics.